New hope for rare vascular conditions: phase 3 drug trial launches
Disease control
Not yet recruiting
This study tests an experimental drug called KP-001 in people aged 2 and older with certain blood vessel or lymphatic malformations (including KTS/CLOVES syndrome). The goal is to see if the drug can shrink these abnormal growths and improve symptoms compared to a placebo. Partic…
Phase: PHASE3 • Sponsor: Kaken Pharmaceutical • Aim: Disease control
Last updated May 17, 2026 08:54 UTC